BMY Annual Cash & Cash Equivalents
$11.46 B
+$2.34 B+25.66%
31 December 2023
Summary:
As of January 22, 2025, BMY annual cash & cash equivalents is $11.46 billion, with the most recent change of +$2.34 billion (+25.66%) on December 31, 2023. During the last 3 years, it has fallen by -$3.08 billion (-21.19%). BMY annual cash & cash equivalents is now -21.19% below its all-time high of $14.55 billion, reached on December 31, 2020.BMY Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMY Quarterly Cash And Cash Equivalents
$7.89 B
+$1.60 B+25.38%
30 September 2024
Summary:
As of January 22, 2025, BMY quarterly cash and cash equivalents is $7.89 billion, with the most recent change of +$1.60 billion (+25.38%) on September 30, 2024. Over the past year, it has dropped by -$3.57 billion (-31.18%). BMY quarterly cash and cash equivalents is now -74.12% below its all-time high of $30.49 billion, reached on September 30, 2019.BMY Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMY Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +25.7% | -31.2% |
| 3 y3 years | -21.2% | -31.2% |
| 5 y5 years | +65.9% | -31.2% |
BMY Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -18.0% | +25.7% | -43.6% | +25.4% |
| 5 y | 5-year | -21.2% | +25.7% | -60.4% | +25.4% |
| alltime | all time | -21.2% | +2147.8% | -74.1% | +1447.1% |
Bristol-Myers Squibb Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $7.89 B(+25.4%) |
| June 2024 | - | $6.29 B(-32.6%) |
| Mar 2024 | - | $9.33 B(-18.6%) |
| Dec 2023 | $11.46 B(+25.7%) | $11.46 B(+52.6%) |
| Sept 2023 | - | $7.51 B(-10.2%) |
| June 2023 | - | $8.37 B(-6.9%) |
| Mar 2023 | - | $8.99 B(-1.4%) |
| Dec 2022 | $9.12 B(-34.7%) | $9.12 B(+18.0%) |
| Sept 2022 | - | $7.73 B(-28.1%) |
| June 2022 | - | $10.75 B(-13.1%) |
| Mar 2022 | - | $12.37 B(-11.5%) |
| Dec 2021 | $13.98 B(-3.9%) | $13.98 B(+3.2%) |
| Sept 2021 | - | $13.54 B(+22.8%) |
| June 2021 | - | $11.02 B(+0.4%) |
| Mar 2021 | - | $10.98 B(-24.5%) |
| Dec 2020 | $14.55 B(+17.8%) | $14.55 B(-25.2%) |
| Sept 2020 | - | $19.43 B(-2.5%) |
| June 2020 | - | $19.93 B(+26.0%) |
| Mar 2020 | - | $15.82 B(+28.1%) |
| Dec 2019 | $12.35 B(+78.6%) | $12.35 B(-59.5%) |
| Sept 2019 | - | $30.49 B(+7.3%) |
| June 2019 | - | $28.40 B(+287.2%) |
| Mar 2019 | - | $7.33 B(+6.1%) |
| Dec 2018 | $6.91 B(+27.5%) | $6.91 B(+27.8%) |
| Sept 2018 | - | $5.41 B(+8.2%) |
| June 2018 | - | $5.00 B(-6.4%) |
| Mar 2018 | - | $5.34 B(-1.5%) |
| Dec 2017 | $5.42 B(+27.9%) | $5.42 B(+16.7%) |
| Sept 2017 | - | $4.64 B(+33.8%) |
| June 2017 | - | $3.47 B(-11.3%) |
| Mar 2017 | - | $3.91 B(-7.7%) |
| Dec 2016 | $4.24 B(+77.7%) | $4.24 B(+23.5%) |
| Sept 2016 | - | $3.43 B(+17.0%) |
| June 2016 | - | $2.93 B(+11.0%) |
| Mar 2016 | - | $2.64 B(+10.9%) |
| Dec 2015 | $2.38 B(-57.2%) | $2.38 B(-40.0%) |
| Sept 2015 | - | $3.98 B(-5.3%) |
| June 2015 | - | $4.20 B(-33.3%) |
| Mar 2015 | - | $6.29 B(+13.0%) |
| Dec 2014 | $5.57 B(+55.4%) | $5.57 B(+14.8%) |
| Sept 2014 | - | $4.85 B(+13.3%) |
| June 2014 | - | $4.28 B(-18.0%) |
| Mar 2014 | - | $5.22 B(+45.7%) |
| Dec 2013 | $3.59 B(+116.5%) | $3.59 B(+102.5%) |
| Sept 2013 | - | $1.77 B(-2.7%) |
| June 2013 | - | $1.82 B(+34.4%) |
| Mar 2013 | - | $1.35 B(-18.2%) |
| Dec 2012 | $1.66 B(-71.3%) | $1.66 B(+10.2%) |
| Sept 2012 | - | $1.50 B(-46.3%) |
| June 2012 | - | $2.80 B(+21.4%) |
| Mar 2012 | - | $2.31 B(-60.1%) |
| Dec 2011 | $5.78 B(+14.8%) | $5.78 B(+29.2%) |
| Sept 2011 | - | $4.47 B(+22.0%) |
| June 2011 | - | $3.67 B(+7.6%) |
| Mar 2011 | - | $3.40 B(-32.3%) |
| Dec 2010 | $5.03 B(-34.5%) | $5.03 B(-15.0%) |
| June 2010 | - | $5.92 B(+15.2%) |
| Mar 2010 | - | $5.13 B(-33.2%) |
| Dec 2009 | $7.68 B(-3.7%) | $7.68 B(+20.7%) |
| Sept 2009 | - | $6.37 B(-15.2%) |
| June 2009 | - | $7.51 B(-4.1%) |
| Mar 2009 | - | $7.83 B(-1.8%) |
| Dec 2008 | $7.98 B(+342.9%) | $7.98 B(+11.2%) |
| Sept 2008 | - | $7.17 B(+77.2%) |
| June 2008 | - | $4.05 B(+65.7%) |
| Mar 2008 | - | $2.44 B(+35.6%) |
| Dec 2007 | $1.80 B(-10.8%) | $1.80 B(+9.4%) |
| Sept 2007 | - | $1.65 B(-30.8%) |
| June 2007 | - | $2.38 B(+7.5%) |
| Mar 2007 | - | $2.21 B(+9.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2006 | $2.02 B(-33.8%) | $2.02 B(-28.8%) |
| Sept 2006 | - | $2.83 B(+8.9%) |
| June 2006 | - | $2.60 B(+5.0%) |
| Mar 2006 | - | $2.48 B(-18.8%) |
| Dec 2005 | $3.05 B(-17.1%) | $3.05 B(+43.3%) |
| Sept 2005 | - | $2.13 B(+18.4%) |
| June 2005 | - | $1.80 B(-45.7%) |
| Mar 2005 | - | $3.31 B(-10.0%) |
| Dec 2004 | $3.68 B(+44.4%) | $3.68 B(+8.8%) |
| Sept 2004 | - | $3.38 B(+7.1%) |
| June 2004 | - | $3.16 B(+3.0%) |
| Mar 2004 | - | $3.06 B(+20.2%) |
| Dec 2003 | $2.55 B(+7.7%) | $2.55 B(-48.5%) |
| Sept 2003 | - | $4.95 B(+15.0%) |
| June 2003 | - | $4.31 B(-0.5%) |
| Mar 2003 | - | $4.33 B(+82.8%) |
| Dec 2002 | $2.37 B(-57.0%) | $2.37 B(-33.5%) |
| Sept 2002 | - | $3.56 B(+0.4%) |
| June 2002 | - | $3.55 B(+4.9%) |
| Mar 2002 | - | $3.38 B(-38.5%) |
| Dec 2001 | $5.50 B(+72.8%) | $5.50 B(+96.4%) |
| Sept 2001 | - | $2.80 B(-4.9%) |
| June 2001 | - | $2.94 B(+11.8%) |
| Mar 2001 | - | $2.63 B(-17.2%) |
| Dec 2000 | $3.18 B(+17.0%) | $3.18 B(+15.3%) |
| Sept 2000 | - | $2.76 B(+24.2%) |
| June 2000 | - | $2.22 B(-10.0%) |
| Mar 2000 | - | $2.47 B(-9.3%) |
| Dec 1999 | $2.72 B(+21.2%) | $2.72 B(+10.8%) |
| Sept 1999 | - | $2.46 B(+18.0%) |
| June 1999 | - | $2.08 B(+3.9%) |
| Mar 1999 | - | $2.00 B(-10.7%) |
| Dec 1998 | $2.24 B(+54.1%) | $2.24 B(+46.6%) |
| Sept 1998 | - | $1.53 B(+52.3%) |
| June 1998 | - | $1.00 B(-35.8%) |
| Mar 1998 | - | $1.56 B(+7.5%) |
| Dec 1997 | $1.46 B(-13.4%) | $1.46 B(-12.5%) |
| Sept 1997 | - | $1.66 B(+11.5%) |
| June 1997 | - | $1.49 B(-17.4%) |
| Mar 1997 | - | $1.81 B(+7.5%) |
| Dec 1996 | $1.68 B(+2.2%) | $1.68 B(+22.9%) |
| Sept 1996 | - | $1.37 B(+21.7%) |
| June 1996 | - | $1.12 B(-13.9%) |
| Mar 1996 | - | $1.30 B(-20.7%) |
| Dec 1995 | $1.65 B(+0.2%) | $1.65 B(-1.7%) |
| Sept 1995 | - | $1.67 B(-2.6%) |
| June 1995 | - | $1.72 B(-2.7%) |
| Mar 1995 | - | $1.77 B(+7.6%) |
| Dec 1994 | $1.64 B(-32.2%) | $1.64 B(-10.9%) |
| Sept 1994 | - | $1.84 B(-16.2%) |
| June 1994 | - | $2.20 B(-12.8%) |
| Mar 1994 | - | $2.52 B(+4.2%) |
| Dec 1993 | $2.42 B(+13.3%) | $2.42 B(+4.0%) |
| Sept 1993 | - | $2.33 B(+8.0%) |
| June 1993 | - | $2.15 B(+32.9%) |
| Mar 1993 | - | $1.62 B(-24.1%) |
| Dec 1992 | $2.14 B(+48.9%) | $2.14 B(+121.0%) |
| Sept 1992 | - | $967.00 M(+18.8%) |
| June 1992 | - | $814.00 M(-30.5%) |
| Mar 1992 | - | $1.17 B(-18.3%) |
| Dec 1991 | $1.44 B(+140.8%) | $1.44 B(+10.4%) |
| Sept 1991 | - | $1.30 B(+19.4%) |
| June 1991 | - | $1.09 B(+79.1%) |
| Mar 1991 | - | $608.00 M(+2.0%) |
| Dec 1990 | $596.00 M(+16.9%) | $596.00 M(-48.6%) |
| Sept 1990 | - | $1.16 B(-5.0%) |
| June 1990 | - | $1.22 B(+30.7%) |
| Mar 1990 | - | $934.00 M(+83.1%) |
| Dec 1989 | $510.00 M(-79.7%) | $510.00 M(-79.7%) |
| Dec 1988 | $2.51 B(+7.0%) | $2.51 B(+7.0%) |
| Dec 1987 | $2.35 B | $2.35 B |
FAQ
- What is Bristol-Myers Squibb annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Bristol-Myers Squibb?
- What is Bristol-Myers Squibb annual cash & cash equivalents year-on-year change?
- What is Bristol-Myers Squibb quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Bristol-Myers Squibb?
- What is Bristol-Myers Squibb quarterly cash and cash equivalents year-on-year change?
What is Bristol-Myers Squibb annual cash & cash equivalents?
The current annual cash & cash equivalents of BMY is $11.46 B
What is the all time high annual cash & cash equivalents for Bristol-Myers Squibb?
Bristol-Myers Squibb all-time high annual cash & cash equivalents is $14.55 B
What is Bristol-Myers Squibb annual cash & cash equivalents year-on-year change?
Over the past year, BMY annual cash & cash equivalents has changed by +$2.34 B (+25.66%)
What is Bristol-Myers Squibb quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of BMY is $7.89 B
What is the all time high quarterly cash and cash equivalents for Bristol-Myers Squibb?
Bristol-Myers Squibb all-time high quarterly cash and cash equivalents is $30.49 B
What is Bristol-Myers Squibb quarterly cash and cash equivalents year-on-year change?
Over the past year, BMY quarterly cash and cash equivalents has changed by -$3.57 B (-31.18%)